Peter Pizzo Net Worth

The estimated Net Worth of Peter J. Iii Pizzo is at least $41.5 Mille dollars as of 13 December 2012. Mr. Pizzo owns over 5,000 units of Alimera Sciences stock worth over $41,475 and over the last 15 years he sold ALIM stock worth over $0. In addition, he makes $0 as Independent Director at Alimera Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Pizzo ALIM stock SEC Form 4 insiders trading

Peter has made over 2 trades of the Alimera Sciences stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ALIM stock worth $7,200 on 13 December 2012.

The largest trade he's ever made was buying 5,000 units of Alimera Sciences stock on 13 December 2012 worth over $7,200. On average, Peter trades about 441 units every 45 days since 2010. As of 13 December 2012 he still owns at least 7,500 units of Alimera Sciences stock.

You can see the complete history of Mr. Pizzo stock trades at the bottom of the page.

Peter Pizzo biography

Peter J. Pizzo III serves as Independent Director of the Company. Pizzo has been a member of the Board since April 2010. Since October 2019, Mr. Pizzo has served as Chief Financial Officer for ControlRad, Inc, a privately held medical technology company focused on reducing unnecessary radiation exposure during fluoroscopically guided procedures. From October 2018 until September 2019, Mr. Pizzo provided financial consulting services to medical device companies. From 2005 until October 2018, Mr. Pizzo served as Chief Financial Officer of Carticept Medical, Inc., a private medical device company, and from its spinout from Carticept in December 2011 until its sale in October 2018, as Chief Financial Officer of Cartiva, Inc., a private orthopedic medical device company. From 2002 until its sale in 2005, Mr. Pizzo served as Chief Financial Officer of Proxima Therapeutics, Inc., a private medical device company. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded global provider of biological products to life science companies, ultimately serving as Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals. From 1992 until its sale in 1995, Mr. Pizzo served in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University. The Board believes that Mr. Pizzo should continue to serve as a director of the Company, in light of its business and structure, for the following reasons: his valuable contributions to the Company in recent years; his years of experience in medical devices, biologics and healthcare services, including in the roles of vice president, finance and chief financial officer.

What's Peter Pizzo's mailing address?

Peter's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, ALPHARETTA, GA, 30005.

Insiders trading at Alimera Sciences

Over the last 15 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo e Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.

What does Alimera Sciences do?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Complete history of Mr. Pizzo stock trades at Alimera Sciences

Alimera Sciences executives and stock owners

Alimera Sciences executives and other stock owners filed with the SEC include:

• Richard Eiswirth,
  President, Chief Executive Officer, Director
• C. Daniel Myers,
  Non-Executive Chairman of the Board
• Richard S. Eiswirth Jr.,
  Pres, CEO & Director
• David Holland,
  Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets
• Philip Ashman,
  Chief Operating Officer, Senior Vice President - Commercial Operations Europe
• David R. Holland,
  Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
• Dr. Philip Ashman,
  COO & Sr. VP of Commercial Operations - Europe
• Charles Daniel Myers,
  Non-Exec. Chairman & Consultant
• James Largent,
  Lead Independent Director
• John Marco,
  Investor Relations
• Mary Szela,
  Independent Director
• John Snisarenko,
  Independent Director
• Peter Pizzo,
  Independent Director
• Garheng Kong,
  Independent Director
• Brian Halak,
  Independent Director
• Samer Kaba,
  Chief Medical Officer
• Phil Jones,
  Chief Financial Officer
• Dr. David Dyer,
  Chief Retina Specialist
• Christopher S. Visick,
  VP, Gen. Counsel & Sec.
• J. Philip Jones,
  Chief Financial Officer
• Calvin W. Roberts,
  Director
• Glen Bradley,
  Director
• James E Deerfield Mgmt L.P....,
  
• Mark J Brooks,
  Director
• Kenneth Green,
  SVP & Chief Scientific Officer
• L.P.Mitchell Kateo'driscoll...,
  
• Alto Investors Lp Palo,
  
• Russell Skibsted,
  Chief Financial Officer & SVP
• Capital, Llc Armistice Capi...,
  
• Patrick Lee,
  10% owner
• Management Viii, L.L.C.Sofi...,
  
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Jesse I Treu,
  10% owner
• Venture Management Co Iv Ll...,
  
• Philip R Tracy,
  Director
• Susan Caballa,
  SEE REMARKS
• Kathleen K Schoemaker,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• Nicole Vitullo,
  10% owner
• Anders D Hove,
  Director
• Bryce Youngren,
  Director
• Brian H Dovey,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Associates Iv L P Venrock M...,
  
• Associates Vi, Llc Mumma Mi...,
  
• Associates Vii, Llc Mumma M...,
  
• Associates V, Llc Mumma Mit...,
  
• L.P.Bock Louis Cmitchell Ka...,
  
• Adam Morgan,
  Director
• Stanley Morgan,
  10% owner
• Todd Michael Wood,
  President of U.S. Operations
• Roger Sawhney,
  Director
• Adam Velan Capital Investme...,
  
• Partners Lpjohnson David Ed...,
  
• Jason M. Werner,
  Chief Operating Officer
• Erin Parsons,
  
• Michael Kaseta,
  
• Ross D De Mont,
  
• Margaret Pax,
  
• Elliot Maltz,
  Chief Financial Officer